

Table: Single-Arm Cohort Studies or Case Series on Mistletoe Treatment in Oncological Diseases (ordered chronologically).[13]

Author, Year	Pre-para-tion ⁱ	Tumor Type ⁱⁱ	Results ⁱⁱⁱ					n ⁱⁱⁱⁱ	Comments ⁱⁱⁱⁱ
			CR	PR	NC	PD	QoL		
Prospective Cohort studies/case series									
Eisenbraun 2009 [5a]	A & CMF/EC/AC	Breast	-	-	-	-	↗	270	Combination of mistletoe and chemotherapy (CMF, EC or AC).
Brandenberger 2008 [4c,d]	X	Various					↗	25	Only abstracts, little information
Eldorrry 2008 [5b]	A, sc, it	HCC	4%	26%	4%	22%		27	44% of patients died before end of therapy. Only abstract
Mansky 2008, 2003 [21]	H & Gem-citabine	Breast, pankreas, colon, lung (NSCLC)	0%	10%	47%	43%		27	Dose-escalation; study primarily on toxicity and pharmacokinetics. Combination of mistletoe and Gemcitabine
Matthes 2007 [25]	H, it	Pancreas	8%	50%	28%	14%	↗	14	Combination of mistletoe and Gemcitabine. Matched Pair Analysis: Survival benefit of 3,2 months
Bar-Sela 2006 [2]	I, ipe	Ascites	Increase of interval between two successive paracenteses from 7 to 12 days, p=0.001				↗	23	Before each paracentesis comparable abdominal circumference and symptom score QOL: Improvement of ascites-associated symptoms
Schink 2006 [35a]	H (& surgery)	Breast, Colon					↗	40	Primarily immunological Study
Kuehn 2005[15]	I	Follicular NH-lymphoma	17%	25%	-	38%		24	Prospective documentation of patients treated 05/99 - 10/03 at the Lukas-klinik; remission under mistletoe monotherapy. In 2009 larger patient group and non-follicular lymphoma with, however, unclear quantifications.
Bar-Sela 2004[1]	A	Colon, rectum	0	0	84%	16%	↗	25	Well documented; advanced disease, 5-Fu-resistant; usual low-dose MT
Mabed 2004 [20]	A	HCC	13%	9%	(39%)*	39%		23	Well documented; inoperable disease, not pre-treated; MT: high dose, 1/week; CP after 4-6 months treatment, duration of CR: 4, 29, 38 months
Montes 2000 [27]	I	Anal condyloma	25%	75%	0	0		4	Only abstract
Mahfouz 1999 [22]	A, sc a./o. it	Breast	8%	54%	35%	4%	↗	26	Well documented; advanced disease, conventionally pre-treated; MT : high dose, 1week
Werner 1999 [39]	A, ip	Pleural effusion	88%				↗	32	Well documented
Mahfouz 1998 [23]	A	Breast, brain	27%	27%	27%	20%	↗	15	Conventionally pre-treated; MT: high dose, 1/week; only abstract
Portalupi 1995 [10,29]	I	CIN I-III	41%	27%	27%	5%		27	Well documented; spontaneous remissions frequent
Friedrichson 1995 [6]	H, ipe	Ascites	70%				↗	12	Unpublished; little information
Stumpf 1994 [36]	H, ip	Pleural effusion	61%	11%	22%			18	Well documented
Kjaer 1989 [14]	I	Kidney	0	0	14%	86%	↘	14	Well documented; usual low dosage; advanced disease; partly concomitant chemotherapy: no remission
Retrospective Cohort studies/case series (or unclear whether prospective or retrospective)									
Matthes 2004 [26]	A it	HCC	28%	33%	17%	22%	↗	18	Good results; only abstract
Montes 2002 [28]	I	Anal condyloma	67% **	33% **				51	Only abstract; unclear information
Kang 2001 [11]	H, ipe	Ascites	100%					10	Only abstract
Kuehn 2001 [16]	I	NH-lymphoma	Favourable long-term cases					30	Positive patient selection possible
Matthes 2001 [24]	H, it	HCC	0	67%	17%	17%		6	Little information

Matthes 2001 [24]	H, it	Hepatic metastases	0	24%	-	-	↗	21	Little information	
Matthes 2001 [24]	H, A it	Pancreas, stomach	~ Doubling of reocclusion time of stent						5	Little information
Matthes 2001 [24]	H, A, ipc	Ascites	17%	-	-			12	Little information	
Matthes 2001 [24]	H, A, ia	Hepatic metastases	0	0	50%	50%	↗	6	Little information	
Schad 2000 [35]	H, I, ipc	Pericardial effusion	(100%)						3	3 case reports, well documented
Wagner 1996 [38]	I	Ovarian	Favourable cases with tumour remission						36	Little information
Wolf 1994 [41]	V, iv	Various					↗	25	Little information	
Hajto 1991, 92 [8, 9]	I	Various	13%	31%	44%	13%	↗	16	Good results; ML I-standardised treatment. little information	
Vehmeyer 1990 [37]	I	Head, Neck	Haematopoiesis ↗						?	Only abstract
Wolf 1987 [40]	V, iv	Various	17%	38%	15%	30%	↗	60	Good results with mistletoe infusion; little information	
Salzer 1977-90 [3, 30-34]	I, ip	Pleural effusion	92%						192	Continuous updating; several case reports; cytologic analyses
Boie 1977 [4a]	H	Melanoma	0	11%	-	-		9	Case series, casuistic description	
Boie 1977 [4b]	H	Multiple myeloma	0	60% **	-	-	↗	5	Case series, casuistic description	
Boie 1977 [4]	H	Prostate	33%	-	-		↗	12	Case series, casuistic description	
Gaubatz 1973 [7]	I	Lung	Median survival: 7,5 (4,2-16) years						9	Unexpected long survival time, gave rise to the RCT by Dold et al. 1991
Leroi 1969 [18]	I	Genitals	5-year survival: 0-92%						77	Survival differentiated with regard to tumour type and stage; little details
Leroi 1958-85 [17, 17a, 19]	I	Urinary bladder	21%						62	Little information; several case reports

ⁱ H: Helixor, A: Abnobaviscum, I: Iscador, V: Vysorel, X: various mistletoe preparations; it: intratumoral, ip: intrapleural, ipc: intrapericardial, ipe: intraperitoneal, ia: intraarterial, iv: intravenous. CMF: Cyclophosphamide, Methotrexate, 5-Fluorouracil; EC: Epirubicin, Cyclophosphamide, AC: Adriamycin, Cyclophosphamide; Unless otherwise stated: subcutaneous

ⁱⁱ Pleural effusion, ascites, and pericardial effusion indicate treatment site; HCC: hepatocellular carcinoma;

ⁱⁱⁱ CR: complete, PR: partial remission, NC: no change, PD: progressive disease, QoL: Quality of life, * not assessable; ** quantification uncertain, information unclear of incomplete

ⁱⁱⁱⁱ n: Number of patients

ⁱⁱⁱⁱⁱ MT: Mistletoe treatment

Dr. med. Gunver S. Kienle
Last Modified: May 2010